Role of dose exposure and inflammatory status in a single center, real-world analysis of sunitinib in patients with metastatic renal cell carcinoma

To evaluate the real-world setting use of sunitinib, we reviewed data of our patients from January 2007 to December 2014. In 114 patients, sunitinib was used as first-line TKI. Out of 110 evaluable patients, 5 complete responses, 37 partial responses, 42 stabilizations were reported. Median progress...

Full description

Saved in:
Bibliographic Details
Published in:Future oncology (London, England) England), 2016-04, Vol.12 (7), p.909-919
Main Authors: Maruzzo, Marco, Basso, Umberto, Diminutto, Alberto, Roma, Anna, Zustovich, Fable, Brunello, Antonella, Fiduccia, Pasquale, Banzato, Alberto, Zattoni, Filiberto, Zagonel, Vittorina
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Antineoplastic Agents - administration & dosage
Antineoplastic Agents - adverse effects
Cancer therapies
Carcinoma, Renal Cell - drug therapy
Carcinoma, Renal Cell - mortality
Carcinoma, Renal Cell - pathology
Chemotherapy
Clinical medicine
Cohort Studies
Disease Progression
dose exposure
Drug dosages
FDA approval
Female
Humans
Immunotherapy
Indoles - administration & dosage
Indoles - adverse effects
Inflammation - pathology
Kidney cancer
Kidney Neoplasms - drug therapy
Kidney Neoplasms - mortality
Kidney Neoplasms - pathology
Lymphocytes
Male
Medical prognosis
Metastasis
Middle Aged
Neoplasm Metastasis
neutrophil-lymphocite ratio
Neutrophils
Oncology
Patients
Pyrroles - administration & dosage
Pyrroles - adverse effects
real world
renal cell carcinoma
sunitinib
survival
Systematic review
Treatment Outcome
Vascular endothelial growth factor
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To evaluate the real-world setting use of sunitinib, we reviewed data of our patients from January 2007 to December 2014. In 114 patients, sunitinib was used as first-line TKI. Out of 110 evaluable patients, 5 complete responses, 37 partial responses, 42 stabilizations were reported. Median progression-free survival and overall survival (OS) were 14.3 and 28.4 months. Patients who received ≥4 full-dose cycles had a better OS (p = 0.02). A neutrophil-lymphocyte ratio
ISSN:1479-6694
1744-8301
DOI:10.2217/fon.16.14